Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jaci.2006.06.018 | DOI Listing |
J Clin Sleep Med
November 2024
Indiana University School of Medicine, Department of Internal Medicine, Division of General Internal Medicine.
Laryngoscope
October 2024
Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health, Detroit, Michigan, U.S.A.
Objective: Topical nasal decongestants (TNDs) are used to reduce nasal soft tissue edema and obstruction. However, after frequent TND use, patients can develop rhinitis medicamentosa (RM) with rebound nasal edema and obstruction. Management of RM has centered largely on TND cessation ± intranasal corticosteroids.
View Article and Find Full Text PDFExpert Opin Pharmacother
October 2024
Department of Otorhinolaryngology & Clinical Allergy Center, The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
Ugeskr Laeger
September 2024
Afdeling for Øre-Næse-Halskirurgi og Audiologi, Københavns Universitetshospital - Rigshospitalet.
J Multidiscip Healthc
March 2024
College of Medicine, Prince Sattam Bin Abdulaziz, Alkharj, Saudi Arabia.
Background: Rhinitis medicamentosa is a nonallergic inflammation of the nasal mucosa caused by topical decongestants overuse. It mainly affects young and middle-aged adults. Therefore, the aim of this study was to investigate the attitudes of pharmacists regarding the utilization of over-the-counter intranasal decongestants.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!